Exactech Inc (EXAC) 27.90 $EXAC 39.8% Return Se
Post# of 273258
Posted On: 09/02/2016 7:05:00 PM
Exactech Inc (EXAC) 27.90 $EXAC
39.8% Return Seen to Date on SmarTrend Exactech Call (EXAC)
Comtex SmarTrend(R) - Mon Aug 29, 1:01PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 5 months, Exactech has returned 39.78% as of today's recent price of $27.97.
EXAC: 27.90 (+0.10)
Exactech Up 41.2% Since SmarTrend Uptrend Call (EXAC)
Comtex SmarTrend(R) - Fri Aug 12, 12:31AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 4 months, Exactech has returned 41.18% as of today's recent price of $28.25.
EXAC: 27.90 (+0.10)
Exactech Up 36.0% Since SmarTrend Uptrend Call (EXAC)
Comtex SmarTrend(R) - Thu Aug 04, 1:02PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 4 months, Exactech has returned 36.03% as of today's recent price of $27.22.
EXAC: 27.90 (+0.10)
Exactech (EXAC) Beats Earnings on Higher Revenues in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:25AM CDT
Exactech Inc. announced adjusted earnings of 31 cents per share in the second quarter of 2016.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), MLAB: 112.17 (-1.21)
Exactech Q2 Revenue Up 8% to $66.1 Million; Net Income up 20% to $4.4 Million; Diluted EPS $0.31 vs. $0.26
BusinessWire - Mon Aug 01, 3:05PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced revenue of $66.1 million for the second quarter of 2016, an 8% increase from $61.5 million in the second quarter of 2015. On a constant currency basis, revenue was up 7%. Net income increased 20% to $4.4 million, or $0.31 per diluted share, compared to $3.7 million, or $0.26 per diluted share, in the same quarter a year ago.
EXAC: 27.90 (+0.10)
Medical Instrument Q2 Earnings on Aug 1: AVGR, EXAC, GKOS
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:57AM CDT
Let's take a look at the major Medical Instrument stocks slated to release their quarterly reports on Aug 1.
AVGR: 4.24 (+0.03), GKOS: 30.69 (+0.62), EXAC: 27.90 (+0.10)
Exactech Shares Up 34.5% Since SmarTrend's Buy Recommendation (EXAC)
Comtex SmarTrend(R) - Thu Jul 28, 12:41AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 4 months, Exactech has returned 34.53% as of today's recent price of $26.92.
EXAC: 27.90 (+0.10)
Exactech Expands Competency in 3-D Printing with Purchase of Arcam Q10plus Systems
BusinessWire - Thu Jun 16, 8:00AM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, has confirmed the purchase of two Arcam Q10plus machines this week to expand its in-house manufacturing capabilities. This investment will advance Exactech's long-term commitment to additive manufacturing technology, also known as 3-D printing.
EXAC: 27.90 (+0.10)
Exactech (EXAC) Scales a 52-Week High on Solid Q1 Results
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 6:58AM CDT
Share price of Exactech Inc (EXAC) reached a new 52-week high of $25.86 on Jun 14.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CRY: 16.23 (+0.39)
Exactech Has Returned 26.6% Since SmarTrend Recommendation (EXAC)
Comtex SmarTrend(R) - Fri Jun 10, 1:24PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 26.59% as of today's recent price of $25.33.
EXAC: 27.90 (+0.10)
DENTSPLY (XRAY) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 6:02AM CDT
Shares of DENTSPLY International Inc. (XRAY) rallied to a new 52-week high of $64.59 on Jun 9.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), XRAY: 61.70 (+0.05)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 3:37AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), TROV: 4.96 (unch), EXAC: 27.90 (+0.10)
Exactech and University of Florida Expand Partnership, Promote Health Education with Naming of "Exactech Arena" at the Stephen C. O'Connell Center
BusinessWire - Thu Jun 09, 3:59PM CDT
Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, announced today an expansion of its long-standing partnership with the University of Florida (UF) through naming of Exactech Arena at the newly remodeled Stephen C. O'Connell Center, a sports and entertainment complex on the university's campus.
EXAC: 27.90 (+0.10)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:39AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), TROV: 4.96 (unch), EXAC: 27.90 (+0.10)
Natus Medical Expands Share Repurchase Program by $20M
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:54AM CDT
Natus Medical Inc. (BABY) recently announced an expansion of its share repurchase program, which authorizes it to buy back additional shares worth $20 million by Jun 1, 2017.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CRY: 16.23 (+0.39)
Exactech Up 24.9% Since SmarTrend Uptrend Call (EXAC)
Comtex SmarTrend(R) - Fri Jun 03, 1:04AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 24.89% as of today's recent price of $24.99.
EXAC: 27.90 (+0.10)
Inogen (INGN) Introduces Next-Gen Inogen One G4 POC
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:15AM CDT
Inogen Inc (INGN) recently launched a next-generation portable oxygen concentrator (POC) -- Inogen One G4.
MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10), CRY: 16.23 (+0.39)
Shares of EXAC Up 21.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 26, 1:34PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 21.24% as of today's recent price of $24.26.
EXAC: 27.90 (+0.10)
Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:44AM CDT
Cynosure Inc. (CYNO) recently announced the receipt of FDA approval for marketing a new Laser Delivery System (LDS) for PicoSure.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), EXAC: 27.90 (+0.10)
39.8% Return Seen to Date on SmarTrend Exactech Call (EXAC)
Comtex SmarTrend(R) - Mon Aug 29, 1:01PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 5 months, Exactech has returned 39.78% as of today's recent price of $27.97.
EXAC: 27.90 (+0.10)
Exactech Up 41.2% Since SmarTrend Uptrend Call (EXAC)
Comtex SmarTrend(R) - Fri Aug 12, 12:31AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 4 months, Exactech has returned 41.18% as of today's recent price of $28.25.
EXAC: 27.90 (+0.10)
Exactech Up 36.0% Since SmarTrend Uptrend Call (EXAC)
Comtex SmarTrend(R) - Thu Aug 04, 1:02PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 4 months, Exactech has returned 36.03% as of today's recent price of $27.22.
EXAC: 27.90 (+0.10)
Exactech (EXAC) Beats Earnings on Higher Revenues in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:25AM CDT
Exactech Inc. announced adjusted earnings of 31 cents per share in the second quarter of 2016.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), MLAB: 112.17 (-1.21)
Exactech Q2 Revenue Up 8% to $66.1 Million; Net Income up 20% to $4.4 Million; Diluted EPS $0.31 vs. $0.26
BusinessWire - Mon Aug 01, 3:05PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced revenue of $66.1 million for the second quarter of 2016, an 8% increase from $61.5 million in the second quarter of 2015. On a constant currency basis, revenue was up 7%. Net income increased 20% to $4.4 million, or $0.31 per diluted share, compared to $3.7 million, or $0.26 per diluted share, in the same quarter a year ago.
EXAC: 27.90 (+0.10)
Medical Instrument Q2 Earnings on Aug 1: AVGR, EXAC, GKOS
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:57AM CDT
Let's take a look at the major Medical Instrument stocks slated to release their quarterly reports on Aug 1.
AVGR: 4.24 (+0.03), GKOS: 30.69 (+0.62), EXAC: 27.90 (+0.10)
Exactech Shares Up 34.5% Since SmarTrend's Buy Recommendation (EXAC)
Comtex SmarTrend(R) - Thu Jul 28, 12:41AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 4 months, Exactech has returned 34.53% as of today's recent price of $26.92.
EXAC: 27.90 (+0.10)
Exactech Expands Competency in 3-D Printing with Purchase of Arcam Q10plus Systems
BusinessWire - Thu Jun 16, 8:00AM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, has confirmed the purchase of two Arcam Q10plus machines this week to expand its in-house manufacturing capabilities. This investment will advance Exactech's long-term commitment to additive manufacturing technology, also known as 3-D printing.
EXAC: 27.90 (+0.10)
Exactech (EXAC) Scales a 52-Week High on Solid Q1 Results
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 6:58AM CDT
Share price of Exactech Inc (EXAC) reached a new 52-week high of $25.86 on Jun 14.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CRY: 16.23 (+0.39)
Exactech Has Returned 26.6% Since SmarTrend Recommendation (EXAC)
Comtex SmarTrend(R) - Fri Jun 10, 1:24PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 26.59% as of today's recent price of $25.33.
EXAC: 27.90 (+0.10)
DENTSPLY (XRAY) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 6:02AM CDT
Shares of DENTSPLY International Inc. (XRAY) rallied to a new 52-week high of $64.59 on Jun 9.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), XRAY: 61.70 (+0.05)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 3:37AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), TROV: 4.96 (unch), EXAC: 27.90 (+0.10)
Exactech and University of Florida Expand Partnership, Promote Health Education with Naming of "Exactech Arena" at the Stephen C. O'Connell Center
BusinessWire - Thu Jun 09, 3:59PM CDT
Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, announced today an expansion of its long-standing partnership with the University of Florida (UF) through naming of Exactech Arena at the newly remodeled Stephen C. O'Connell Center, a sports and entertainment complex on the university's campus.
EXAC: 27.90 (+0.10)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:39AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), TROV: 4.96 (unch), EXAC: 27.90 (+0.10)
Natus Medical Expands Share Repurchase Program by $20M
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:54AM CDT
Natus Medical Inc. (BABY) recently announced an expansion of its share repurchase program, which authorizes it to buy back additional shares worth $20 million by Jun 1, 2017.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CRY: 16.23 (+0.39)
Exactech Up 24.9% Since SmarTrend Uptrend Call (EXAC)
Comtex SmarTrend(R) - Fri Jun 03, 1:04AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 24.89% as of today's recent price of $24.99.
EXAC: 27.90 (+0.10)
Inogen (INGN) Introduces Next-Gen Inogen One G4 POC
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:15AM CDT
Inogen Inc (INGN) recently launched a next-generation portable oxygen concentrator (POC) -- Inogen One G4.
MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10), CRY: 16.23 (+0.39)
Shares of EXAC Up 21.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 26, 1:34PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 21.24% as of today's recent price of $24.26.
EXAC: 27.90 (+0.10)
Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:44AM CDT
Cynosure Inc. (CYNO) recently announced the receipt of FDA approval for marketing a new Laser Delivery System (LDS) for PicoSure.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), EXAC: 27.90 (+0.10)
(0)
(0)Scroll down for more posts ▼